Sugi Predict

Sugi Predict / Compounds / SCHEMBL18650698

SCHEMBL18650698

SCHEMBL18650698

COC1O[C@H](CO[C@@H]2O[C@H](CO[C@@H]3O[C@H](CO[C@@H]4O[C@H](CO[C@@H]5O[C@H](CO[C@@H]6O[C@H](C=O)[C@@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.44

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ M6PR P20645 2/20 0.44
▸ G6PD P11413 3/20 0.42
▸ IGF2R P11717 4/20 0.40
▸ GAA P10253 1/20 0.39
▸ CDK1 P06493 1/20 0.39
▸ CCNB1 P14635 1/20 0.39
▸ CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17254892 1.00 M6PR (0.44) M6PRG6PDIGF2RGAACDK1
SCHEMBL18654279 1.00 M6PR (0.44) M6PRG6PDIGF2RGAACDK1
SCHEMBL15700171 0.85 M6PR (0.56) M6PRG6PDCA2
SCHEMBL8615533 0.85 M6PR (0.56) M6PRG6PDCA2
SCHEMBL19502333 0.85 M6PR (0.56) M6PRG6PDCA2
SCHEMBL15698043 0.85 M6PR (0.56) M6PRG6PDCA2
SCHEMBL20143964 0.85 M6PR (0.56) M6PRG6PDCA2
SCHEMBL16710457 0.82 GAA (0.44) G6PDIGF2RGAACDK1CCNB1
SCHEMBL17247216 0.82 GAA (0.44) G6PDIGF2RGAACDK1CCNB1
SCHEMBL14091411 0.82 GAA (0.44) G6PDIGF2RGAACDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266609-B2 Immunomodulating beta-1,6-D-glucans INNATE BIOTHERAPEUTICS, LLC (US) 2019-04-23 — — US disclosed
US-20170081428-A1 IMMUNOMODULATING BETA-1,6-D-GLUCANS INNATE BIOTHERAPEUTICS, LLC 2017-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266609-B2 Immunomodulating beta-1,6-D-glucans IFNG, FUT6, LGALS1 M6PR 146/4885G6PD 12/4885IGF2R 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.